Compare › Wegovy vs Saxenda
Wegovy vs Saxenda
Wegovy is semaglutide; Saxenda is liraglutide. Different molecules, different sponsors, separate FDA applications. What follows is what the public record holds on each.
| Wegovy | Saxenda | |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| FDA application | NDA215256, NDA218316 | NDA206321 |
| First FDA action | 2021-06-04 | 2014-12-23 |
| Sponsor | Novo Nordisk | Novo Nordisk |
| EU authorisation | Wegovy | Saxenda |
| FDA supply status | No open records | 1 to be discontinued |
| FDA actions on file | 54 | 20 |
| Active trials of the molecule | 203 | 17 |
Everything above is a field from Drugs@FDA, the FDA Drug Shortage Database, the EMA register or ClinicalTrials.gov. There is no efficacy comparison here and there will not be one: head-to-head claims belong to the trials that made them, and which drug suits a particular person is a question for a clinician.
Full records: Wegovy · Saxenda · semaglutide · liraglutide